Clinical Trials on Diabetic Glomerulosclerosis in Argentina

Total 281 results

Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Diabetes Mellitus Type 2

Colombia, United States, Mexico, Guatemala, Argentina
Eli Lilly and Company

Completed

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) (AWARD-8)

Type 2 Diabetes Mellitus

Argentina, United States, Mexico, Croatia, Austria, Romania, South Africa, Slovenia
AstraZeneca

Completed

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

Type 2 Diabetes

United States, Argentina, Mexico, Israel
Eli Lilly and Company

Completed

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Diabetes Mellitus, Type 2

Turkey, Argentina, Korea, Republic of, Brazil, China, Egypt, India, Spain
Hoffmann-La Roche

Completed

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab (ALTIMETER)

Diabetic Macular Edema

Germany, United States, United Kingdom, Argentina, Canada, Italy, Poland
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Terminated

Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD) (iINHALE 8)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Chronic Obstructive Pulmonary Disease

Slovakia, Argentina, India, Turkey, Romania, Taiwan, Thailand
Novo Nordisk A/S

Completed

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Romania, Slovakia, Israel, Saudi Arabia, India, Malaysia, Mexico, Russian Federation, Germany, Croatia, Poland, Serbia, Bulgaria, Canada, Slovenia, Sweden, Denmark, Hungary, Argentina, Austria, Finland, Lebanon, Czechia, Netherlands
AstraZeneca

Completed

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Type 2 Diabetes

United States, Mexico, Puerto Rico, Israel, Sweden, Italy, Philippines, Argentina
Phenomix

Unknown

A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Argentina, Canada, India, Mexico
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Diabetes Mellitus Type 2

United States, Mexico, Argentina
Eli Lilly and Company

Completed

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes (IOOZ)

Diabetes Mellitus, Type 1

Russian Federation, United States, Australia, Greece, Argentina, Hungary, Brazil, Mexico, Romania
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Type 2 Diabetes Mellitus

China, Mexico, Argentina
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes (SimpleMix™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Poland, Spain, India, Argentina, China
CymaBay Therapeutics, Inc.

Completed

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

Type 2 Diabetes

United States, Israel, Argentina, India
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

India, Macedonia, The Former Yugoslav Republic of, Malaysia, Turkey, Croatia, Bulgaria, Romania, Australia, South Africa, Argentina
Phenomix
Forest Laboratories

Terminated

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Type 2 Diabetes

United States, Malaysia, Peru, India, Argentina, Philippines, Romania, Ukraine
Novo Nordisk A/S

Completed

Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin (SIT2MIX)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, India, Malaysia, Turkey, Argentina, Greece, Australia, Portugal, Thailand, Brazil
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

Type 2 Diabetes

Sweden, France, Italy, Mexico, South Africa, Spain, Germany, Netherlands, Argentina, United Kingdom
Phenomix
Forest Laboratories

Terminated

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

Type 2 Diabetes Mellitus

United States, Argentina, India, Peru, Poland, Czech Republic
Hoffmann-La Roche

Active, not recruiting

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

Diabetic Macular Edema

United Kingdom, Korea, Republic of, United States, Argentina, Poland, Puerto Rico, Israel, Spain, Canada
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
Eli Lilly and Company

Recruiting

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Type 2 Diabetes

United States, Argentina, United Kingdom, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Argentina, Slovakia, Greece, South Africa, Australia
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
Sanofi

Completed

Obese Patients With Type 2 Diabetes (RIO-Diabetes)

Obesity | Diabetes Mellitus, Non-Insulin-Dependent | Obesity in Diabetes

United States, France, Canada, Poland, Germany, Netherlands, Belgium, Czech Republic, Argentina, Finland, United Kingdom
ActivX Biosciences, Inc.
Kyorin Pharmaceutical Co.,Ltd

Completed

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone (Synergy104)

Type 2 Diabetes

United States, Poland, Argentina, Russian Federation, Czech Republic, South Africa, Guatemala
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Australia, France, Italy, Korea, Republic of, Mexico, Spain, Poland, Romania, South Africa, Argentina, Austria, Belgium, Germany, Hungary, Israel, Slovakia, Greece, India, Taiwan, Canada, Czech Republic
AstraZeneca
Eli Lilly and Company

Completed

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Estonia, Romania, Finland, Netherlands, Argentina, Belgium, Germany, Portugal, United Kingdom, Greece, France, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
Boehringer Ingelheim

Completed

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Diabetes Mellitus, Type 2

United States, Argentina, Hungary, India, Japan, Poland, Russian Federation
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Sweden, Malaysia, France, Netherlands, India, Argentina, South Africa, Romania, Former Serbia and Montenegro, Austria, Czech Republic, Philippines, Mexico
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

Mexico, United States, Argentina, Brazil, Canada
Novo Nordisk A/S

Terminated

Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes (iINHALE 7)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Mexico, Poland, Canada, Austria, Belgium, Argentina, France, Bulgaria, Turkey
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (QWINT-1)

Type 2 Diabetes | T2D

United States, Mexico, Argentina, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen (Full STEP™)

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Argentina, Macedonia, The Former Yugoslav Republic of, Slovenia, Canada, Brazil
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)

Type 2 Diabetes | Type 2 Diabetes Treated With Insulin

United States, Germany, Mexico, Argentina, Puerto Rico, Italy, Spain, India
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Diabetes Mellitus

China, United States, Canada, Mexico, Russian Federation, Croatia, United Kingdom, Argentina, Australia, India, South Africa, Greece, Ukraine, Romania, Italy, Hong Kong, Former Serbia and Montenegro, Brazil
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Diabetes Mellitus, Type II | Diabetes Mellitus, Non Insulin Dependent

United States, Poland, Bulgaria, India, Malaysia, Romania, Canada, Russian Federation, Argentina, Puerto Rico, Czech Republic, United Kingdom, Mexico
Eli Lilly and Company

Completed

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Germany, Poland, Argentina, Puerto Rico
Takeda

Terminated

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Argentina, Mexico, Chile, Peru
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Croatia, Italy, Slovakia, Denmark, Macedonia, The Former Yugoslav Republic of, Norway, Russian Federation, Finland, France, Poland, Greece, Romania, Sweden, Czech Republic, Argentina
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (PIONEER 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Austria, Belgium, Norway, Turkey, Switzerland, Argentina, Korea, Republic of, Brazil, Egypt
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (SURPASS-3)

Type 2 Diabetes Mellitus

United States, Korea, Republic of, Taiwan, Italy, Austria, Puerto Rico, Hungary, Greece, Poland, Spain, Romania, Ukraine, Argentina
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)

Type 2 Diabetes Mellitus

United States, Hungary, Puerto Rico, Spain, Australia, Korea, Republic of, Mexico, Japan, Germany, Russian Federation, Taiwan, Slovakia, Argentina, Czechia, India, Italy

Clinical Trials on Diabetic Glomerulosclerosis in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations